TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3106927

Group type: EXPERIMENTAL
Intervention: Lactaid (3,250 neutral lactose units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Takamine (6,635 food and chemical codex lactose units)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prehydrolyzed milk (standard of reference)
Number of subjects: 0
Study: 29653523

Group type: EXPERIMENTAL
Intervention: Video-based transdiagnostic REBT universal prevention program
Number of subjects: 338

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 338
Study: 28811749

Group type: EXPERIMENTAL
Intervention: Cocoa Flavanols (900 mg CF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (13 mg CF)
Number of subjects: 12
Study: 26142368

Group type: EXPERIMENTAL
Intervention: Novel navigated ultrasound (NUS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional ultrasound (CUS)
Number of subjects: 44
Study: 23217729

Group type: EXPERIMENTAL
Intervention: Lamotrigine (25mg/day, increasing to 200mg/day by week 6)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21393051

Group type: EXPERIMENTAL
Intervention: Static cyclotorsion compensation (SCC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no static cyclotorsion compensation)
Number of subjects: 70
Study: 18458645

Group type: EXPERIMENTAL
Intervention: Bilateral oophorectomy with no previous hormone therapy use
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Unilateral or partial oophorectomy
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) use within 5 years of bilateral oophorectomy
Number of subjects: 1064

Group type: COMPARATOR
Intervention: No hormone therapy use
Number of subjects: 1064
Study: 17176186

Group type: EXPERIMENTAL
Intervention: Mother-daughter intervention program for improving rapport
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer program rated favorably by intervention arm girls and mothers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 15315266

Group type: EXPERIMENTAL
Intervention: SKI306X 200 mg three times daily
Number of subjects: 249

Group type: COMPARATOR
Intervention: Diclofenac 100 mg sustained release once daily
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: SKI306X
Number of subjects: 249

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 249
Study: 11751710

Group type: COMPARATOR
Intervention: Dexamethasone (1 mg) - acute administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexamethasone (1 mg) - prolonged administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo - acute administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo - prolonged administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexamethasone (1 mg) - prolonged administration in lean subjects
Number of subjects: 40
Study: 9252087

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: colchicine
Number of subjects: 88

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 88
Study: 8344108

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 820

Group type: COMPARATOR
Intervention: Emergency sclerotherapy
Number of subjects: 820
Study: 3738655

Group type: EXPERIMENTAL
Intervention: Vincristine sulphate bolus of 1.5 mg/m2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vincristine sulphate
Number of subjects: 40
Study: 28629268

Group type: EXPERIMENTAL
Intervention: Cawthorne-Cooksey exercises (n=24)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Frenkel exercises (n=23)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine care (control group, n=25)
Number of subjects: 72
Study: 27106972

Group type: EXPERIMENTAL
Intervention: SARI (Simplified Airway Risk Index)
Number of subjects: 64273

Group type: COMPARATOR
Intervention: Usual airway assessment (Non-SARI)
Number of subjects: 64273
Study: 25488080

Group type: EXPERIMENTAL
Intervention: Computerized fetal heart rate (FHR) analysis with interactive advice to the operator
Number of subjects: 2869

Group type: EXPERIMENTAL
Intervention: Computerized fetal heart rate (FHR) analysis
Number of subjects: 2869
Study: 21871635

Group type: EXPERIMENTAL
Intervention: Zinc sulfate dispersible tablets (5 mg Zn)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Zinc sulfate solution (5 mg Zn/5 mL)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 451
Study: 20976374

Group type: EXPERIMENTAL
Intervention: Aspirin - 200 mg/day (Group Aspirin - GA)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Warfarin at individually-adjusted doses (Group Warfarin - GW)
Number of subjects: 229
Study: 18545068

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg coadministered with simvastatin 20 mg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Simvastatin 20 mg (monotherapy)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ezetimibe and simvastatin group
Number of subjects: 144

Group type: COMPARATOR
Intervention: Simvastatin monotherapy group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with simvastatin
Number of subjects: 144
Study: 11329544

Group type: EXPERIMENTAL
Intervention: Rhythm Stabilizing Algorithm (RSA) during baseline AF (pacer set to default V/VI 50/min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low clinically indicated pacing rate (69+/‐9 beats/min) after ablation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rapid regular pacing at mean preablation rate (110+/‐18 beats/min) after ablation
Number of subjects: 11
Study: 9758072

Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica 30x
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 7930468

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg bid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-treated (Control)
Number of subjects: 36
Study: 3339948

Group type: EXPERIMENTAL
Intervention: Veralipride (200 mg/day for 20 days) + Naloxone (1.6 mg/h for 4 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 0
Study: 31205195

Group type: EXPERIMENTAL
Intervention: Asenapine (10-20 mg/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/d)
Number of subjects: 120
Study: 28161384

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (BG 100‐140mg/dl [5.5‐7.8mM])
Number of subjects: 288

Group type: COMPARATOR
Intervention: Conservative glucose control (BG 141‐180mg/dl [7.9‐10.0mM])
Number of subjects: 288
Study: 26236676

Group type: EXPERIMENTAL
Intervention: Supervised tooth brushing under the supervision of parents (Group A)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Supervised tooth brushing under the supervision of a caregiver (Group B)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Supervised tooth brushing under the supervision of both investigator and caregiver (Group C)
Number of subjects: 315
Study: 24280442

Group type: EXPERIMENTAL
Intervention: Huai Qi Huang (HQH)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 45
Study: 21623250

Group type: EXPERIMENTAL
Intervention: Distance base-out (BO) break
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Near base-out (BO) break
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Distance base-in (BI) break
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Near base-in (BI) break
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Distance phoria
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Near phoria
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Distance interpupillary distance (IPD)
Number of subjects: 114
Study: 18441705

Group type: EXPERIMENTAL
Intervention: Coraxan
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 95
Study: 16585867

Group type: EXPERIMENTAL
Intervention: Preoperative accelerated hyperfractionated radiotherapy with concurrent cisplatin followed immediately by surgery and intraoperative radiotherapy, completed with early postoperative weekly paclitaxel, two additional cisplatin cycles, and concurrent once‐daily radiotherapy beginning on day 28 after surgery
Number of subjects: 43
Study: 12897503

Group type: EXPERIMENTAL
Intervention: Color Doppler Ultrasonography
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (16 individuals without spine deformity)
Number of subjects: 36
Study: 10845965

Group type: EXPERIMENTAL
Intervention: Trim and fill fixed effects analysis method
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Random effects model
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Publication bias adjustment
Number of subjects: 48
Study: 9148534

Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Inspiratory Resistance-Positive Expiratory Pressure (IR-PEP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine chest physiotherapy alone
Number of subjects: 66
Study: 10779311

Group type: EXPERIMENTAL
Intervention: Levocabastine eye-drops
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31494289

Group type: EXPERIMENTAL
Intervention: Implementation of a brachial plexus biological dose constraint in IMPT plans (cohort B).
Number of subjects: 51

Group type: COMPARATOR
Intervention: IMPT plans without BP biological dose constraint (cohort A).
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MCBD plans (cohort B).
Number of subjects: 51

Group type: COMPARATOR
Intervention: Eclipse plans (cohort B).
Number of subjects: 51
Study: 29258851

Group type: EXPERIMENTAL
Intervention: Synthetic granular calcium phosphate compound (CPC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bovine mineral
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Composite bisphosphonate‐linked hyaluronic acid‐calcium phosphate hydrogel (HABP·CaP)
Number of subjects: 18
Study: 26767377

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Non-training controls
Number of subjects: 287
Study: 24723582

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 939

Group type: COMPARATOR
Intervention: Normal LVM
Number of subjects: 939
Study: 23006960

Group type: EXPERIMENTAL
Intervention: BIA guided fluid management (BCM measurements every 2 months)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: BIA guided fluid management
Number of subjects: 1300
Study: 20418695

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.50% ropivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: saline (Group S)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 120
Study: 17904420

Group type: EXPERIMENTAL
Intervention: Optimal CPAP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham-CPAP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Optimal CPAP (in patients with obstructive sleep apnea)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham-CPAP (in patients with obstructive sleep apnea)
Number of subjects: 60
Study: 16622086

Group type: COMPARATOR
Intervention: T-Gel 0.1% MD (multidose)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: T-Gel 0.1% SDU (single dose unit)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Both treatments (T-Gel 0.1% MD and T-Gel 0.1% SDU)
Number of subjects: 175
Study: 12793022

Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine nerve ablation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Presacral neurectomy
Number of subjects: 24
Study: 11379470

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 19
Study: 8800102

Group type: EXPERIMENTAL
Intervention: Precordial ST segment depression (in leads V1 to V3, V4 to V6, or both)
Number of subjects: 16521

Group type: COMPARATOR
Intervention: No precordial ST segment depression
Number of subjects: 16521

Group type: EXPERIMENTAL
Intervention: Magnitude of precordial ST segment depression
Number of subjects: 16521
Study: 1320521

Group type: EXPERIMENTAL
Intervention: sodium valproate
Number of subjects: 228

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 228
Study: 6529776

Group type: EXPERIMENTAL
Intervention: Terconazole (R-42470) cream 0.4%
Number of subjects: 78

Group type: COMPARATOR
Intervention: Clotrimazole cream 1%
Number of subjects: 78
Study: 31450520

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT), Nordic walking (NW), and therapeutic touch (TT)
Number of subjects: 17
Study: 30400858

Group type: EXPERIMENTAL
Intervention: Hypertension awareness
Number of subjects: 4485

Group type: EXPERIMENTAL
Intervention: Hypertension treatment
Number of subjects: 4485

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 4485

Group type: EXPERIMENTAL
Intervention: Prevalence of hypertension
Number of subjects: 4485
Study: 25060395

Group type: EXPERIMENTAL
Intervention: Rocker outsole shoe (with a toe‐only rocker sole)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline shoe (without a rocker outsole)
Number of subjects: 17
Study: 25715484

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir
Number of subjects: 0
Study: 23110478

Group type: EXPERIMENTAL
Intervention: Topical Negative Pressure (TNP) with dermal substitute
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Topical Negative Pressure (TNP) without dermal substitute
Number of subjects: 86

Group type: COMPARATOR
Intervention: Dermal substitute without TNP
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no dermal substitute, no TNP)
Number of subjects: 86
Study: 20213205

Group type: EXPERIMENTAL
Intervention: Primary care office-based buprenorphine/naloxone treatment (dosage and duration not specified)
Number of subjects: 166
Study: 17541206

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) for approximately 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 25
Study: 15738287

Group type: EXPERIMENTAL
Intervention: COPD patients (ex-smokers and continuing smokers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsmoking controls
Number of subjects: 0
Study: 11825814

Group type: EXPERIMENTAL
Intervention: Brimonidine, 0.2%, twice a day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Latanoprost, 0.005%, every day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 115
Study: 9585684

Group type: EXPERIMENTAL
Intervention: Abdominal binder and electrical stimulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Abdominal binder
Number of subjects: 24

Group type: COMPARATOR
Intervention: Voluntary coughing
Number of subjects: 24
Study: 7649149

Group type: EXPERIMENTAL
Intervention: Running (R)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cross-training (XT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study: 2651758

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 at a dose of 0.25 to 0.5 microgram daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 610977

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo-acupuncture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atrovent (parasympatholytic drug)
Number of subjects: 12
Study: 27834264

Group type: EXPERIMENTAL
Intervention: Guided disclosure protocol (3 sessions of 20 minutes each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control condition (3 sessions of 20 minutes each)
Number of subjects: 0
Study: 28804985

Group type: EXPERIMENTAL
Intervention: Virtual Reality Cue Exposure Therapy (CET)
Number of subjects: 64

Group type: COMPARATOR
Intervention: A-CBT
Number of subjects: 64
Study: 25921095

Group type: EXPERIMENTAL
Intervention: General quadriceps exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Specific-VM exercise
Number of subjects: 50
Study: 22505251

Group type: EXPERIMENTAL
Intervention: sTWEAK levels
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: sTWEAK levels in patients with severe vascular calcification (CACs ≥400)
Number of subjects: 131
Study: 21829501

Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy (WBC) for 96 h post-exercise, repeated each day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 11
Study: 19203988

Group type: COMPARATOR
Intervention: Lactobacillus rhamnosus 35 (Lcr35) 0 CFU/day (Control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 2 x 10(8) CFU/day (Low-dose group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 6 x 10(8) CFU/day (High-dose group)
Number of subjects: 23
Study: 16758382

Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam 4.5 g
Number of subjects: 300

Group type: COMPARATOR
Intervention: Piperacillin 4 g
Number of subjects: 300

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Piperacillin and Piperacillin/Tazobactam
Number of subjects: 300
Study: 14561107

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 0
Study: 10988100

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microgram, twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8792357

Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1% eye drops
Number of subjects: 120

Group type: COMPARATOR
Intervention: N-acetyl aspartyl glutamic acid 6% (NAAGA) drops
Number of subjects: 120
Study: 1610573

Group type: EXPERIMENTAL
Intervention: Forced-air warmer (43 degrees C, blanket covering legs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Circulating-water blanket (40 degrees C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heated humidifier (40 degrees C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no extra warming)
Number of subjects: 20
Study: 6531660

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg (initial loading dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine H2-receptor antagonists (high doses)
Number of subjects: 0
Study: 31498177

Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS) 2.0 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30650617

Group type: EXPERIMENTAL
Intervention: Portable non-invasive ventilation (pNIV) during recovery
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Portable non-invasive ventilation (pNIV) after 12 weeks
Number of subjects: 24
Study: 25387324

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: End-exercise Blood Lactate (La)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: End-exercise Blood pH
Number of subjects: 32
Study: 22974968

Group type: EXPERIMENTAL
Intervention: 60 min of morning exercise at 60% VO(2peak)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study: 22102856

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AM-LM)
Number of subjects: 474
Study: 17964785

Group type: EXPERIMENTAL
Intervention: Overall Neuropathy Limitations Scale (ONLS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10‐m timed walk (T10MW)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 9‐hole‐peg test (9‐HPT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contraction (MVIC) of arm (elbow flexion, hand‐grip, and three‐point pinch)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contraction (MVIC) of leg (knee extension, foot dorsiflexion/plantar flexion)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Foot dorsiflexion using an immobilization device
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Foot plantar flexion using an immobilization device
Number of subjects: 40
Study: 16571960

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg or greater
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 27
Study: 12749830

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 1600/45 microg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Formoterol 45 microg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11764220

Group type: EXPERIMENTAL
Intervention: Rofecoxib (COX-2 specific inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9432788

Group type: EXPERIMENTAL
Intervention: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative dosage increased by 50% (single dose - 6 Gy; total dose - 30 Gy; 54 isoGy) for stomach cancer
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative dosage increased by 25% (single dose - 5 Gy; total dose - 25 Gy; 40 isoGy) for colonic cancer
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative irradiation with a single HRT dose of 10 Gy (28 isoGy) for breast tumors reduced time of irradiation 4 times
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Radiotherapy as a control procedure - 357 patients
Number of subjects: 1280
Study: 8217066

Group type: EXPERIMENTAL
Intervention: levoprotiline
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: maprotiline
Number of subjects: 58

Group type: COMPARATOR
Intervention: complementary drug treatment for non-responders
Number of subjects: 58